Thursday, November 26

The Oxford vaccine is safe and elicits immune response in older people | Society



agencies | drafting

They have reached that conclusion in a preliminary analysis published in the journal ‘The Lancet’. Phase 3 trials are now underway to confirm these results.

The vaccine being developed by the University of Oxford (United Kingdom) and the company AstraZeneca against SARS-CoV-2, the virus that generates COVID-19, has shown similar safety and immunogenicity results in healthy older adults (56 years or older) to those observed in adults aged 18 to 55, according to a preliminary analysis published in the reputed scientific journal The Lancet.

In this phase 2 trial, the vaccine has been found to cause few side effects and induces immune responses in both parts of the immune system in all age groups and at low and standard doses, eliciting a T-cell response within 14 days of the first dose of the vaccine (i.e., an immune response cell, which could find and attack cells infected with the virus), and an antibody response within 28 days of the booster dose of the vaccine (i.e., a humoral immune response, which could find and attack to the virus when it is circulating in the blood or lymphatic system).

Now, phase 3 trials are underway to confirm these results, as well as the efficacy of the vaccine in protecting against SARS-CoV-2 infection, in a wider range of people, including older adults with underlying health problems.

“Immune responses to vaccines tend to decline in older adults because the immune system gradually deteriorates with age, which also makes older adults more susceptible to infections. Therefore, it is crucial that COVID-19 vaccines be tested in this group which is also a priority group for immunization, “explains the study’s lead author, Professor Andrew Pollard, from the University of Oxford.

Adverse reactions to the vaccine were mild (the most common effects were pain and tenderness at the injection site, fatigue, headache, fever, and muscle pain). Adverse effects were less common in older adults than in younger ones.

T-cell responses against the SARS-CoV-2 spike protein peaked 14 days after the first vaccination, regardless of age and standard or low dose of the vaccine.

The authors point out some limitations of your study, among them that participants in the oldest age group had a mean age of 73-74 years and few underlying health problems, so they may not be representative of the general elderly population, including people living in centers residential care or are over 80 years old.

Follow the recommendationss against the coronavirus from the health authorities. In the face of fake news, pay attention only to official sources. If you live in the CAV and have symptoms, call your usual health center. The Health Council will also attend to people on the phone 900 20 30 50, offering information and solving doubts about the coronavirus. If you live in Navarra, call the Health Council phone number: 948 290 290. Remember, the most effective way to prevent the spread of COVID-19 is hand washing. Masks are mandatory in the CAV from July 16, and in Navarra from July 17. In Iparralde it is mandatory in closed public spaces, public transport and in the most important municipalities and cities.

style="display:block" data-ad-client="ca-pub-3066188993566428" data-ad-slot="4073357244" data-ad-format="auto" data-full-width-responsive="true">

Leave a Reply

Your email address will not be published. Required fields are marked *